This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PALO ALTO, Calif., June 17, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the JMP Securities Healthcare Conference 2014. Ocera's presentation is scheduled for Wednesday, June 25, 2014 at 12:30 PM ET in the Consulate presentation room.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website,
www.ocerainc.com . A replay of the presentation will be available for 30 days following the conference for those unable to listen live.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger under development for the treatment of hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. The FDA has granted Orphan Disease and Fast Track status to OCR-002. For additional information, please see
CONTACT: Inquiries: Gaurav Aggarwal, MD
Ocera Therapeutics, Inc.